You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Increasing use of ketamine as a recreational drug in Asia, Europe, and America is a great burden on society at large, leading to aspirational strain, unemployment, and crime. These societal effects have led to growing interest among researchers and clinicians in ketamine's effects on various systems of the body. Ketamine: Use and Abuse reviews the
None
New York Times best-selling author Dr. Mike Dow and Ronan Levy, founder of Field Trip, the world's largest provider of psychedelic-assisted psychotherapies, offer ways to integrate ketamine into treatment for depression, anxiety, PTSD, and more. It’s been described as the most important breakthrough in mental health since the introduction of Prozac in 1986. And though once considered taboo, the psychedelic compound, ketamine, is experiencing a spectacular therapeutic comeback. When combined with psychotherapy, ketamine, which has been described as the being possibly the “most important breakthrough in antidepressant treatment in decades,” has the potential to treat depression, anxiety,...
The emergence of ketamine--previously known as a combat anesthetic and club drug--as a treatment for depression. Ketamine, approved in 2019 by the Food and Drug Administration for the treatment of depression, has been touted by scientists and media reports as something approaching a miracle cure. This volume in the MIT Press Essential Knowledge series chronicles the ascent of a drug that has been around for fifty years--in previous incarnations, a Vietnam-era combat anesthetic and a popular club drug--that has now been reinvented as a treatment for depression. Bita Moghaddam, a leading researcher in neuropharmacology, explains the scientific history and the biology of ketamine, its clinical use, and its recently discovered antidepressant effects, for the nonspecialist reader.
None
Ketamine, also called K, Special K, and Kit Kat, causes bizarre experiences unlike any other psychedelic drug. The Little Book of Ketamine describes the recreational and spiritual use of Ketamine, including: What K is, how it is made, and how it is used; How K affects the brain; Hallucinations, near-death and out-of-body experiences; Spiritual enlightenment through K and afterlife experiences; Dosages, administration, and safety precautions; Accounts of K-Trips by experienced users; How it feels to go to K-Land; Ketamine and the law. The Little Book of Ketamine reviews the history of Ketamine from its discovery to its use in night clubs and raves, as well as describing extraordinary stories of Ketamine's effects while being mindful of what is myth and what is reality. "Ketamine is a very odd and intriguing entheogen, outpacing all others in sheer range of experience and utter strangeness. It unlocks powers so intense and improbable it is hard to believe such a substance could even exist." —James Kent TRP
This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants. --
This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and c...
Some important constraints of anesthesia must be taken into consideration when the pharmacological properties of modern anesthetics are discussed. The most imp- tant of these could be that the target effect be achieved preferably within seconds, at most within a few minutes. Similarly, offset of drug action should be achieved within minutes rather hours. The target effects, such as unconsciousness, are pot- tially life-threatening, as are the side effects of modern anesthetics, such as respi- tory and cardiovascular depression. Finally, the patient’s purposeful responses are not available to guide drug dosage, because, either the patient is unconscious, or more problematically, the patient...
This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.